Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/105852
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bernardes de Jesus, Bruno | - |
dc.contributor.author | Neves, Bruno Miguel | - |
dc.contributor.author | Ferreira, Manuela | - |
dc.contributor.author | Nóbrega-Pereira, Sandrina | - |
dc.date.accessioned | 2023-03-13T09:01:25Z | - |
dc.date.available | 2023-03-13T09:01:25Z | - |
dc.date.issued | 2020-11-30 | - |
dc.identifier.issn | 2072-6694 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/105852 | - |
dc.description.abstract | Despite improvements in cancer therapy, metastatic solid tumors remain largely incurable. Immunotherapy has emerged as a pioneering and promising approach for cancer therapy and management, and in particular intended for advanced tumors unresponsive to current therapeutics. In cancer immunotherapy, components of the immune system are exploited to eliminate cancer cells and treat patients. The recent clinical successes of immune checkpoint blockade and chimeric antigen receptor T cell therapies represent a turning point in cancer treatment. Despite their potential success, current approaches depend on efficient tumor antigen presentation which are often inaccessible, and most tumors turn refractory to current immunotherapy. Patient-derived induced pluripotent stem cells (iPSCs) have been shown to share several characteristics with cancer (stem) cells (CSCs), eliciting a specific anti-tumoral response when injected in rodent cancer models. Indeed, artificial cellular reprogramming has been widely compared to the biogenesis of CSCs. Here, we will discuss the state-of-the-art on the potential implication of cellular reprogramming and iPSCs for the design of patient-specific immunotherapeutic strategies, debating the similarities between iPSCs and cancer cells and introducing potential strategies that could enhance the efficiency and therapeutic potential of iPSCs-based cancer vaccines. | pt |
dc.description.sponsorship | European Commission (ERA-CVD Joint Call 2018, grant#INNOVATION) through FCT and the Portuguese Ministry of Health, through the Directorate General of Health (DGS) | pt |
dc.language.iso | eng | pt |
dc.publisher | MDPI | pt |
dc.relation | LISBOA-01-0145-FEDER-028534 | pt |
dc.relation | UIDB/04501/2020 | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt |
dc.subject | iPSCs | pt |
dc.subject | cancer | pt |
dc.subject | reprogramming | pt |
dc.subject | immunotherapy | pt |
dc.subject | neoantigens | pt |
dc.subject | vaccines | pt |
dc.title | Strategies for Cancer Immunotherapy Using Induced Pluripotency Stem Cells-Based Vaccines | pt |
dc.type | article | - |
degois.publication.firstPage | 3581 | pt |
degois.publication.issue | 12 | pt |
degois.publication.title | Cancers | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.3390/cancers12123581 | pt |
degois.publication.volume | 12 | pt |
dc.date.embargo | 2020-11-30 | * |
uc.date.periodoEmbargo | 0 | pt |
item.fulltext | Com Texto completo | - |
item.grantfulltext | open | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.openairetype | article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.project.grantno | Aveiro Institute of Biomedicine - iBiMED | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
crisitem.author.orcid | 0000-0001-9498-8061 | - |
Appears in Collections: | I&D CNC - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Strategies-for-cancer-immunotherapy-using-induced-pluripotency-stem-cellsbased-vaccinesCancers.pdf | 1.54 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License